STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs
STAT
NOVEMBER 17, 2023
They were approved under the FDA accelerated pathway in 2009 and 2014, respectively, for treating a rare form of blood cancer. The The company’s final study plan was submitted to the FDA in 2022 and is expected to be completed by 2030 , according to FDA briefing documents published earlier this week.
Let's personalize your content